Inspire Medical Systems (NYSE:INSP) Releases FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 1.050-1.450 for the period, compared to the consensus earnings per share estimate of 0.910. The company issued revenue guidance of $835.0 million-$875.0 million, compared to the consensus revenue estimate of $848.9 million.

Inspire Medical Systems Stock Performance

INSP opened at $60.77 on Wednesday. The stock’s 50 day moving average price is $46.59 and its 200-day moving average price is $54.97. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of 13.53, a P/E/G ratio of 5.29 and a beta of 0.70. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.86%. The company had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. During the same quarter last year, the business posted $0.45 EPS. The firm’s revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts predict that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on INSP. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price for the company. in a report on Friday, May 22nd. Robert W. Baird upped their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a report on Tuesday. Truist Financial reaffirmed a “hold” rating and set a $62.00 price objective (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday. UBS Group assumed coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price on the stock. Finally, Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus price target of $68.00.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported second-quarter EPS of $0.14, significantly above the consensus estimate for a $0.24 loss, while revenue of $200.6 million also exceeded expectations of $194.7 million. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: The company raised fiscal 2026 EPS guidance to $1.05-$1.45, above the roughly $0.91 analyst consensus. Revenue guidance of $835 million-$875 million was broadly in line with expectations, reinforcing confidence in earnings growth and the company’s strategic growth plan. Inspire Announces Second Quarter Results and Raised Guidance
• Positive Sentiment: Oppenheimer upgraded Inspire from “market perform” to “outperform” and set an $85 price target, implying substantial upside from recent trading levels. Mizuho also raised its target to $65 and maintained an “outperform” rating.
• Neutral Sentiment: JPMorgan raised its price target from $54 to $60 but retained a “neutral” rating, while Robert W. Baird increased its target from $54 to $59 and also remained neutral. The mixed ratings suggest analysts see improving fundamentals but limited near-term valuation support.
• Negative Sentiment: Revenue declined 7.6% year over year, and the company continues to face U.S. reimbursement pressures. Earnings also fell from $0.45 per share in the comparable quarter, tempering the otherwise strong outlook.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its holdings in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the last quarter. Larson Financial Group LLC raised its holdings in Inspire Medical Systems by 21,266.7% during the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after purchasing an additional 638 shares in the last quarter. Quarry LP lifted its position in shares of Inspire Medical Systems by 695.1% during the 4th quarter. Quarry LP now owns 644 shares of the company’s stock worth $59,000 after buying an additional 563 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 130 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Inspire Medical Systems by 349.7% during the 4th quarter. Parallel Advisors LLC now owns 715 shares of the company’s stock worth $66,000 after acquiring an additional 556 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.